Testing new drug combo for first-line extensive small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive stage small cell lung cancer (meaning the cancer has spread beyond the lung where it started).
- You must not have had any previous treatment for your lung cancer.
- You must be able to care for yourself (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You must not have active or symptomatic brain metastases, or a history of lung inflammation that required steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.